Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Goldman Sachs Maintains Neutral on BioNTech, Lowers Price Target to $156

Goldman Sachs analyst Chris Shibutani maintains BioNTech (NASDAQ:BNTX) with a Neutral and lowers the price target from $177 to $156.
byBenzinga Newsdesk
January 31, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Goldman Sachs analyst Chris Shibutani maintains BioNTech (NASDAQ:BNTX) with a Neutral and lowers the price target from $177 to $156.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Over $14M Bet On Diversified Healthcare Trust? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

By Lisa Levin
June 12, 9:25 AM
The Dow Jones closed higher by over 40 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

ADVM

Read More

Asia Closes In Green, Europe Trades Higher and Crude Ticks Up – Global Markets Today While US Was Sleeping

By Akanksha Bakshi
August 29, 6:47 AM
On Monday, August 28, the U.S. markets closed higher, with most sectors on the S&P 500 closing on a positive note. The manufacturing general business activity index for Texas, as reported by the Federal Reserve Bank of Dallas, increased to -17.2 in August, surpassing the anticipated value of -21.6.

EEMA